Laboratorios Farmaceuticos Rovi (LABFF) Stock Price, News & Analysis

Company Overview

Laboratorios Farmacéuticos Rovi, S.A. is a Spanish pharmaceutical company headquartered in Madrid. Founded in 1946, the company researches, develops, manufactures and markets prescription medicines, proprietary pharmaceutical products and healthcare solutions for Spain and international markets.

Rovi’s portfolio includes products for areas such as thrombosis prevention and treatment, respiratory health and other specialty-care indications. Its best-known proprietary medicine is bemiparin, a low-molecular-weight heparin marketed under the Hibor brand in several countries. The company has also developed risperidone ISM, a long-acting injectable treatment for schizophrenia marketed in selected markets under brands including Okedi.

In addition to its own products, Rovi operates pharmaceutical manufacturing and contract development services through its industrial operations. These activities include the production and packaging of injectable medicines and other complex pharmaceutical formulations for third-party companies. Rovi expanded its manufacturing role during the COVID-19 pandemic by providing fill-and-finish services for Moderna’s mRNA vaccine in Spain. The company is led by executive chairman Juan López-Belmonte Encina.

Key Stats

• Today's Range: C$67.17 to C$67.17
• 50-Day Range: C$67.17 to C$67.17
• 52-Week Range: C$65.86 to C$67.17
• Volume: N/A
• Average Volume: 1,300 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:LABFF
• CIK: N/A
• Web: www.rovi.es
• Phone: 34 91 021 30 00
• Fax: N/A
• Employees: 2,232
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A